Nektar Therapeutics
Financials
Valuation Metrics
Nektar Therapeutics's Market Cap is $2.27B. At end of 2025 it was $858M. Ranked #1927 of 3,121 in US market (top 62%), #725 of 1,463 on NASDAQ (top 50%), #124 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 47%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.27B | US#1,927/3,121 Sec#124/266 |
| Revenue | $55M | US#2,764/3,121 Sec#144/266 |
| Net Income | $-157M | US—/3,121 Sec—/266 |
| Total Assets | $1.10B | US#2,436/3,121 Sec#98/266 |
| Net Assets | $903M | US#1,837/3,121 Sec#73/266 |
| Employees | 63 | US#2,689/3,121 Sec#200/266 |
| Value | ||
| P/B | 2.51x | US#1,562/3,121 Sec#73/266 |
| P/S | 41.53x | US#2,906/3,121 Sec#160/266 |
| FCF Yield | -10.32% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -17.40% | US#2,463/3,121 Sec#95/266 |
| ROA | -14.35% | US#2,739/3,121 Sec#114/266 |
| Op. Margin | -240.38% | US#2,782/3,121 Sec#141/266 |
| Revenue Growth | -27.15% | US#2,710/3,121 Sec#156/266 |
| Financial Health | ||
| Debt Ratio | 21.26% | US#244/3,121 Sec#83/266 |
| Total Debt | $136M | US#2,357/3,121 Sec#105/266 |
| FCF | $-234M | US#2,805/3,121 Sec#219/266 |
| Cash | $39M | US#2,683/3,121 Sec#239/266 |
| Current Ratio | 10.42x | US#244/3,121 Sec#77/266 |
| Performance | ||
| 1Y Return | 14.19% | US#825/3,121 Sec#133/266 |
| 1M Return | -11.80% | US#2,085/3,121 Sec#160/266 |
| From 52W High | -38.44% | US#2,385/3,121 Sec#183/266 |
| 1Y MDD | -46.54% | US#2,306/3,121 Sec#166/266 |
| Trading | ||
| Volume | 2,683,656 shares | US#1,367/3,121 Sec#146/266 |
| Trading Value | $182M | US#1,039/3,121 Sec#74/266 |
| Per Share | ||
| EPS | $-4.65 | US—/3,121 Sec—/266 |
| BPS | $26.73 | US#988/3,121 Sec#20/266 |
Company Info
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.